ArticleTranslational cancer research2025
Application value of a prognostic risk model based on lactate-related genes in non-small cell lung cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite therapeutic advances, the outcomes of patients with advanced disease are still poor. This study was conducted to identify pathogenic and prognostic lactate-related genes (LRGs) in NSCLC to improve clinical treatment and prognosis. Methods: Consensus clustering was applied to The Cancer Genome Atlas (TCGA) training cohort to delineate subtypes associated with lactate metabolism. On this basis, we established a prognostic signature of LRGs with least absolute shrinkage and selection operator (LASSO) Cox regression and assessed its predictive value in independent Gene Expression Omnibus (GEO) datasets. To clarify the mechanisms related to the model's ability, we examined immune infiltration, estimated responses to immunotherapy, and performed single-cell analysis. In addition, the transcriptional levels of the prognostic genes were validated via real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) in lung cancer cell lines and compared with alveolar epithelial cells (AECs), thereby strengthening the reliability of the model. Results: Two distinct lactate-associated clusters were identified in NSCLC. On this basis, we established an eight-gene prognostic model that stratified patients into high- and low-risk groups with markedly different survival outcomes. The model achieved strong predictive accuracy, with areas under the curve of 0.693, 0.707, and 0.704 for 1-, 3-, and 5-year survival in the training cohort, and its robustness was further confirmed in external validation datasets. In addition, the lactate risk score showed significant associations with the tumor microenvironment (TME) and revealed clear differences in responsiveness to immunotherapy. Single-cell analysis provided further insight into cell type-specific patterns of lactate metabolism. Finally, RT-qPCR validation of most prognostic genes confirmed the reliability of the model. Conclusions: We developed an LRG prognostic model for NSCLC, which offers novel insights for both diagnostic assessment and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.